Emergent BioSolutions Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter earnings report. Unless noted, amounts are in U.S. dollars.
Business context
Emergent develops and supplies public-health-threat countermeasures, including government-procured medical countermeasures (MCMs), NARCAN naloxone nasal spray, and contract development and manufacturing services (Bioservices). In Q4 2023, it realigned reporting into Commercial Products, MCM Products, and Services segments. The U.S. Government remained its largest customer, representing approximately 38% of FY2023 revenue.
In May 2023, Emergent sold its travel health business to Bavarian Nordic for $270.2 million in cash, recognized a $74.2 million pretax gain, and may receive additional contingent payments. It also reduced its workforce through two restructuring plans and shifted strategy to reduce investment in and de-emphasize Bioservices as a growth engine.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $1,049.3 million | $1,117.5 million | Down 6% |
| Operating loss | $726.4 million | $170.0 million | Loss widened |
| Net loss | $760.5 million | $211.6 million | Loss widened |
| Net loss per diluted share | $14.85 | $4.22 | Loss widened |
| Net cash used in operating activities | $206.3 million | $34.1 million | Use increased |
| Cash and cash equivalents at year-end | $111.7 million | $642.6 million | Down 83% |
| Gross debt reported in debt note | $868.4 million | $1,413.8 million | Down 39% |
| Working capital | $28.2 million | $(18.5) million | Improved |
Segment gross margin fell to $317.6 million from $383.0 million, and its margin rate declined to 31% from 36%. Commercial Products revenue rose 29% to $497.3 million, primarily on higher NARCAN sales; MCM Products revenue fell 23% to $447.2 million; Services revenue fell 29% to $78.5 million. Services continued to report a gross loss of $111.0 million.
The net loss included non-cash impairment charges of $306.7 million for Bioservices long-lived assets and $218.2 million for MCM goodwill. Interest expense rose to $87.9 million from $37.3 million. The travel-health sale gain partly offset these and other expenses.
At December 31, 2023, the balance sheet showed $413.7 million of current debt and $446.5 million of debt net of current portion. The company reported $80.3 million of unused revolving-credit capacity. Cash fell substantially despite sale proceeds, as operating cash use and debt repayments drove a $530.9 million net decrease in cash and restricted cash during the year.
Material changes and outlook
- NARCAN revenue increased 30% to $487.5 million; the OTC product launched in U.S. retail and online channels in August 2023. Generic and branded competition, pricing pressure, and demand uncertainty remain material risks.
- MCM revenue declined amid product and delivery timing, including lower anthrax and smallpox sales. Emergent delivered approximately $120 million of ACAM2000 under a 2023 government option.
- FDA approved CYFENDUS in July 2023. BARDA awarded a 10-year Ebanga development, manufacturing-scale-up, and procurement contract with a maximum potential value of approximately $704 million, subject to options. In January 2024, the company announced a BioThrax DoD IDIQ contract with a maximum value of $235.8 million.
- Management said cost-reduction actions are expected to produce more than $160 million in annualized savings when fully implemented. The company provided no clear consolidated revenue or earnings guidance in the supplied filing text.
Going concern, risks, and unusual items
- Substantial doubt about going concern: The company concluded substantial doubt exists about its ability to continue as a going concern within one year after issuance of the financial statements. It was out of compliance with a minimum EBITDA covenant at year-end and did not expect to meet a requirement to raise at least $75 million by April 30, 2024. Secured facilities mature in May 2025.
- Forbearance: On February 29, 2024, lenders agreed to a limited forbearance and amendment, generally through April 30, 2024, subject to conditions. Management said future covenant compliance would require additional liquidity or further amendments. Failure to resolve defaults could lead to acceleration and cross-default under the 2028 unsecured notes, with insolvency proceedings identified as a possible outcome.
- Legal matters: Securities and shareholder derivative litigation related to past COVID-19 manufacturing claims remains pending, alongside government inquiries. Loss amounts were not reasonably estimable. In the Janssen contract dispute, Emergent reported $158.8 million of related long-term assets, no related accounts receivable, and no contingent liability recorded for Janssen’s allegations; the dispute is proceeding through arbitration.
- Manufacturing and quality: The FDA closed the Camden facility warning letter after a 2023 inspection; Canton received a VAI classification, while Lansing’s inspection classification was not yet determined in the filing. Three RSDL lots recalled in November 2022; Emergent reported remediation and awaited formal FDA closure.
- Reporting and controls: The company restated FY2022 financial statements after identifying errors, including a state deferred-tax calculation issue. It reported that the weakness was remediated by year-end 2023, and management and the auditor concluded internal control over financial reporting was effective as of December 31, 2023.
- Other risks include reliance on U.S. government appropriations and contract options, single-source suppliers, variable product-delivery timing, unprofitable Bioservices operations, potential future impairments, and an October 2023 business-partner access incident whose potential impact was still under assessment.
Most important facts for investors to verify
- Current liquidity, covenant status, financing needs, and the outcome of lender negotiations following the limited forbearance period.
- Whether the company can meet debt obligations and sustain operations without asset sales, new capital, or further lender relief.
- Actual NARCAN OTC demand, net pricing, channel returns, and the effect of generic and branded competition.
- Government funding, option exercises, delivery schedules, and margins for CYFENDUS, BioThrax, ACAM2000, and other MCM contracts.
- Progress and financial effects of the Bioservices retrenchment, cost savings, and any further asset impairments or disposals.
- Developments in the Janssen arbitration, shareholder litigation, government investigations, facility inspections, and the RSDL recall closure.